Ularitide in Acute Heart Failure

AbstractPurpose of ReviewThis review article will summarize the currently available data for ularitide in acute decompensated heart failure (ADHF).Recent FindingsHospitalization for ADHF represents a key prognostic event in the time course of many patients with HF. It is associated with a high risk for rehospitalization (~  50% at 6 months) and 1-year mortality rate (~ 30%).SummaryThere is an unmet need for agents that will improve symptoms and outcomes for clinical outcomes in ADHF. Several agents with vasodilating properties have been studied in this population, but there is limited data demonstrating definitive efficacy of currently available therapies. Ularitide is a synthetic form of urodilatin, a natriuretic peptide produced in the distal renal tubule cells.
Source: Current Emergency and Hospital Medicine Reports - Category: Emergency Medicine Source Type: research